Merck's New Drugs Valued at Over $70 Billion
Merck's (MRK) stock has seen significant growth in the past year, returning 96% compared to the S&P 500's 16.8%. With shares currently 4.0% below their 52-week high, investors are looking for reasons why Merck can continue growing. Management highlighted the company's new drugs as its biggest opportunity, citing a group of over 20 products with a commercial potential valued at over $70 billion.
Two notable examples of these new drugs are WINREVAIR and WELIREG, which saw sales increase by 75% and 67%, respectively. While still growing from small figures, management is optimistic about their potential impact on Merck's portfolio. KEYTRUDA, the company's cancer drug, accounts for half of Merck's revenue but faces a loss of exclusivity in the early 2030s.
Merck's market value is $367.3 billion, with a price-to-sales ratio of 5.5 times its sales over the past year. This premium valuation suggests that investors are confident in the company's new drugs, but management has acknowledged potential risks such as trial failures and regulatory issues.